{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}],"title":"CR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"CRi"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"PR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"Complete remission (CR) - includes patients with good CR and CR with minimal residual disease (MRD); remission with incomplete blood count recovery (CRi), partial remission (PR)","groups":[{"description":"Patients receive pravastatin sodium PO QD on days 1-8, idarubicin IV over 10-15 minutes on days 4-6, and cytarabine IV continuously on days 4-7. Treatment repeats every 28-56 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.\n\npravastatin sodium: Given PO\n\nidarubicin: Given IV\n\ncytarabine: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Pravastatin Sodium, Idarubicin, and Cytarabine)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All patient who received IAP treatment were assessed for response. The number of participants with CR, CRi and PR are included in the table below.","reportingStatus":"POSTED","timeFrame":"35 days","title":"Rate of Complete Remission (CR), Remission With Incomplete Blood Count Recovery (CRi) and Partial Remission (PR)","type":"SECONDARY","unitOfMeasure":"Participants"}